Silence Therapeutics plc (NASDAQ:SLN) Expected to Announce Earnings of -$0.62 Per Share

Brokerages predict that Silence Therapeutics plc (NASDAQ:SLNGet Rating) will post ($0.62) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Silence Therapeutics’ earnings. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Silence Therapeutics will report full-year earnings of ($2.02) per share for the current financial year, with EPS estimates ranging from ($2.38) to ($1.37). For the next year, analysts forecast that the company will post earnings of ($2.58) per share, with EPS estimates ranging from ($2.86) to ($2.30). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Silence Therapeutics.

Silence Therapeutics (NASDAQ:SLNGet Rating) last issued its quarterly earnings results on Thursday, March 17th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.20. The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $2.74 million.

SLN has been the subject of several research reports. Zacks Investment Research downgraded shares of Silence Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 25th. HC Wainwright decreased their price target on Silence Therapeutics from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, March 22nd. Finally, Chardan Capital started coverage on Silence Therapeutics in a research note on Thursday, March 31st. They issued a “buy” rating and a $33.00 price target for the company.

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in Silence Therapeutics during the fourth quarter worth approximately $157,000. Morgan Stanley increased its stake in Silence Therapeutics by 11.0% in the third quarter. Morgan Stanley now owns 10,615 shares of the company’s stock valued at $218,000 after purchasing an additional 1,050 shares during the period. SG Americas Securities LLC raised its holdings in shares of Silence Therapeutics by 135.1% in the third quarter. SG Americas Securities LLC now owns 12,702 shares of the company’s stock valued at $275,000 after buying an additional 7,300 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth about $1,092,000. Finally, Blair William & Co. IL boosted its stake in shares of Silence Therapeutics by 26.1% during the fourth quarter. Blair William & Co. IL now owns 56,026 shares of the company’s stock worth $1,338,000 after buying an additional 11,582 shares during the period. 6.54% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SLN opened at $10.75 on Wednesday. The firm has a fifty day simple moving average of $16.35 and a two-hundred day simple moving average of $20.19. Silence Therapeutics has a twelve month low of $9.00 and a twelve month high of $35.00.

About Silence Therapeutics (Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.

Recommended Stories

Get a free copy of the Zacks research report on Silence Therapeutics (SLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.